HGEN
Price:
$0.0361
Market Cap:
$4.30M
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is also being studied in conjunction with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Dis...[Read more]
Industry
Biotechnology
IPO Date
2013-01-31
Stock Exchange
NASDAQ
Ticker
HGEN
According to Humanigen, Inc.’s latest financial reports and current stock price. The company's current ROE is 46.59%. This represents a change of 79.55% compared to the average of 25.95% of the last 4 quarters.
The mean historical ROE of Humanigen, Inc. over the last ten years is 105.51%. The current 46.59% ROE has changed -55.84% with respect to the historical average. Over the past ten years (40 quarters), HGEN's ROE was at its highest in in the September 2016 quarter at 2.44%. The ROE was at its lowest in in the March 2016 quarter at -1761.69%.
Average
105.51%
Median
85.83%
Minimum
-617.20%
Maximum
1.01%
Discovering the peaks and valleys of Humanigen, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 299.79%
Maximum Annual ROE = 1.01%
Minimum Annual Increase = -605.51%
Minimum Annual ROE = -617.20%
Year | ROE | Change |
---|---|---|
2022 | 150.19% | -85.11% |
2021 | 1.01% | -605.51% |
2020 | -199.52% | -345.36% |
2019 | 81.32% | -45.06% |
2018 | 148.01% | 63.83% |
2017 | 90.35% | -85.36% |
2016 | 617.01% | -199.97% |
2015 | -617.20% | 299.79% |
2014 | -154.38% | 122.79% |
2013 | -69.29% | -379.85% |
The current ROE of Humanigen, Inc. (HGEN) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
319.75%
5-year avg
237.72%
10-year avg
105.51%
Humanigen, Inc.’s ROE is less than Acer Therapeutics Inc. (0%), less than NRx Pharmaceuticals, Inc. (196.73%), less than Pasithea Therapeutics Corp. (193.11%), greater than SAB Biotherapeutics, Inc. (-74.63%), greater than Windtree Therapeutics, Inc. (-94.04%), greater than Dermata Therapeutics, Inc. (-123.93%), greater than Ensysce Biosciences, Inc. (-197.44%), greater than Panbela Therapeutics, Inc. (-705.90%), less than Baudax Bio, Inc. (545.45%), less than Avenue Therapeutics, Inc. (54.54%), greater than Hoth Therapeutics, Inc. (-749.10%), greater than Revelation Biosciences, Inc. (-81.79%), greater than NeuroBo Pharmaceuticals, Inc. (-243.91%), greater than Virax Biolabs Group Limited (-154.04%), greater than Cardio Diagnostics Holdings, Inc. (-115.10%), greater than NovaBay Pharmaceuticals, Inc. (-308.99%), greater than Oncorus, Inc. (-431.13%), greater than eFFECTOR Therapeutics, Inc. (-130.61%), less than Apollomics, Inc. (2.18%), greater than Angion Biomedica Corp. (-184.11%), greater than Sigilon Therapeutics, Inc. (-113.71%), greater than null (-81.98%),
Company | ROE | Market cap |
---|---|---|
0% | $22.02M | |
196.73% | $17.73M | |
193.11% | $4.37M | |
-74.63% | $26.21M | |
-94.04% | $1.66M | |
-123.93% | $2.08M | |
-197.44% | $4.23M | |
-705.90% | $1.75M | |
545.45% | $8.13M | |
54.54% | $4.05M | |
-749.10% | $7.32M | |
-81.79% | $1.43M | |
-243.91% | $29.70M | |
-154.04% | $15.24M | |
-115.10% | $6.94M | |
-308.99% | $2.18M | |
-431.13% | $3.14M | |
-130.61% | $188.18K | |
2.18% | $14.97M | |
-184.11% | $30.11M | |
-113.71% | $56.22M | |
-81.98% | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Humanigen, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Humanigen, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Humanigen, Inc.'s ROE?
How is the ROE calculated for Humanigen, Inc. (HGEN)?
What is the highest ROE for Humanigen, Inc. (HGEN)?
What is the 3-year average ROE for Humanigen, Inc. (HGEN)?
What is the 5-year average ROE for Humanigen, Inc. (HGEN)?
How does the current ROE for Humanigen, Inc. (HGEN) compare to its historical average?